Shionogi Chief Expresses Eagerness for COVID-19 Drug Rollout, PII/III to Wrap Up by Year-End

Shionogi President Isao Teshirogi said on September 29 that his company plans to complete a recently initiated PII/III study for its oral COVID-19 drug by the end of the year and start preparations for its regulatory submission in Japan. Dr...read more